Bio-Techne Corp
$ 63.82
1.38%
03 Dec - close price
- Market Cap 9,943,967,000 USD
- Current Price $ 63.82
- High / Low $ 64.72 / 63.10
- Stock P/E 130.24
- Book Value 12.62
- EPS 0.49
- Next Earning Report 2026-02-03
- Dividend Per Share $0.32
- Dividend Yield 0.51 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.04 %
- 52 Week High 78.83
- 52 Week Low 45.80
About
Bio-Techne Corporation (Ticker: TECH) is a leading global provider of high-quality life science reagents, instruments, and services, with a strategic emphasis on clinical diagnostics and research. Headquartered in Minneapolis, Minnesota, the company leverages advanced technologies to drive innovation in critical domains such as genomics, proteomics, and cellular analysis. Catering to a diverse clientele that includes academic institutions, pharmaceutical companies, and clinical laboratories, Bio-Techne is positioned as a key player in the advancement of scientific research and diagnostic solutions worldwide, fostering growth and development in the life sciences industry.
Analyst Target Price
$69.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-10-30 | 2024-08-07 | 2024-05-01 | 2024-02-01 | 2023-10-31 | 2023-08-08 | 2023-05-03 | 2023-02-02 |
| Reported EPS | 0.42 | 0.53 | 0.56 | 0.42 | 0.42 | 0.49 | 0.48 | 0.4 | 0.41 | 0.55 | 0.53 | 0.47 |
| Estimated EPS | 0.43 | 0.5 | 0.51 | 0.39 | 0.38 | 0.49 | 0.45 | 0.41 | 0.44 | 0.55 | 0.53 | 0.62 |
| Surprise | -0.01 | 0.03 | 0.05 | 0.03 | 0.04 | 0 | 0.03 | -0.01 | -0.03 | 0 | 0 | -0.15 |
| Surprise Percentage | -2.3256% | 6% | 9.8039% | 7.6923% | 10.5263% | 0% | 6.6667% | -2.439% | -6.8182% | 0% | 0% | -24.1935% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.4355 |
| Currency | USD |
Previous Dividend Records
| Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Jan 1970 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-11-28 | 2025-08-29 | 2025-05-30 | 2025-02-28 | None | 2024-11-22 | 2024-08-30 | 2024-05-24 | 2024-02-26 | 2023-11-24 |
| Amount | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TECH
2025-12-04 12:09:35
Russell Investments Group Ltd. has reduced its stake in Bio-Techne Corp by selling 23,984 shares, leaving them with 142,902 shares valued at approximately $7.35 million. While Bio-Techne's recent quarterly EPS matched estimates, revenue fell short. The company maintains a "Moderate Buy" consensus rating from analysts with a target price of $70.92.
2025-12-04 11:49:49
Norges Bank has purchased a new stake in Bio-Techne Corp (NASDAQ:TECH), acquiring 1,909,395 shares valued at approximately $98.24 million during the second quarter. This move makes Norges Bank a significant institutional investor in the biotechnology company, holding about 1.22% of Bio-Techne's stock. Other institutional investors also adjusted their positions in Bio-Techne, which recently announced a quarterly dividend of $0.08 per share and had analysts weigh in on its stock performance.
2025-12-02 10:52:26
Edgestream Partners L.P. increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 15.9% in Q2, now holding 229,625 shares valued at $11.81 million. Institutional investors own approximately 98.95% of the company, and analysts have a "Moderate Buy" rating with a consensus price target of $70.92. Bio-Techne reported $0.42 EPS in line with estimates and declared a quarterly dividend of $0.08 per share.
2025-12-02 10:07:13
Capital Fund Management S.A. recently acquired a new stake of 95,046 shares in Bio-Techne Corp (NASDAQ:TECH) valued at approximately $4.89 million during the second quarter. This investment makes Capital Fund Management S.A. a significant institutional holder, owning about 0.06% of Bio-Techne. The article also details other institutional investor activities, analyst ratings, and Bio-Techne's recent financial performance and dividend announcement.
2025-12-01 12:19:08
Mackenzie Financial Corp increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 2.9% to 2,619,101 shares, valued at approximately $134.8 million. This comes amidst a "Moderate Buy" average analyst rating and updated price targets from several firms. Bio-Techne reported Q3 EPS of $0.42, meeting estimates, and revenue of $286.6 million, slightly below expectations.
2025-12-01 10:33:34
Rhumbline Advisers reduced its stake in Bio-Techne Corp by 1.9% in Q2, ending the quarter with 294,621 shares valued at $15.16 million. Bio-Techne reported Q2 EPS of $0.42 and revenue of $286.56 million, slightly below estimates. The company has a "Moderate Buy" rating from analysts with a consensus price target near $70.92.
